Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Back to dashboard
Company Information
About this company
Key people
Thomas William Burns
Chairman of the Board, Chief Executive Officer
Joseph E. Gilliam
President, Chief Operating Officer
Alex R. Thurman
Chief Financial Officer, Senior Vice President
Tomas Navratil
Chief Development Officer
Mark J. Foley
Lead Independent Director
David F. Hoffmeister
Independent Director
Gilbert H. Kliman
Independent Director
Marc A. Stapley
Independent Director
Denice M. Torres
Independent Director
Click to see more
Key facts
- Shares in issue59.01m
- EPICGKOS
- ISINUS3773221029
- LocationUnited States
- SectorHealthcare
- IndustryMedical Equipment & Supplies
- Market cap$9.72bn
- Employees1,094
- ExchangeNew York Stock Exchange
- IndexS&P 600 Small Cap, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.